BRCA genetic testing and treatment patterns for patients with HER2-negative early-stage breast cancer in the US community setting
<i>BRCA</i>m testing rates in the US remain suboptimal relative to practice guideline recommendations and availability of adjuvant targeted therapy for HER2-negative eBC. Particular areas of unmet need include <i>BRCA</i>m testing for HR+/HER2-negative eBC, in addition to TNBC, and improving the timeline of <i>BRCA</i>m testing by implementing genetic testing before surgery to inform treatment decisions.
Authors
- Kim M. Hirshfield (ORCID: https://orcid.org/0000-0002-5848-1316)
- Kathryn Mishkin (ORCID: https://orcid.org/0000-0003-0050-8106)
- Ke Meng (ORCID: https://orcid.org/0000-0002-9213-7439)
- Jagadeswara Rao Earla (ORCID: https://orcid.org/0000-0002-6688-5273)
- Qixin Li (ORCID: https://orcid.org/0009-0007-4522-1594)
- Jaime Mejia (ORCID: https://orcid.org/0000-0002-1315-6878)
- Yu-Han Kao
- X. Xu
- Y. Sun
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fonc.2026.1730548
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00